Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Test Detects Early Mouth Cancer

By LabMedica International staff writers
Posted on 24 Oct 2012
Print article
A gene test that can detect precancerous cells in patients with benign-looking mouth lesions could potentially allow at-risk patients to receive earlier treatment, significantly improving their chance of survival.

The test is less invasive than the standard histopathology methods as it requires only a 1-2 mm piece of tissue and it takes less than three hours to get the results, compared to up to a week for standard histopathology where biopsy tissue taken during an operation is examined under a microscope by a pathologist.

Scientists at Queen Mary, University of London (UK) showed that the quantitative Malignancy Index Diagnostic System (qMIDS) test had a cancer detection rate of 91% to 94% when used on more than 350 head and neck tissue specimens from 299 patients in the UK and Norway. The qMIDS test measures the levels of 16 genes, which are converted, via a diagnostic algorithm, into a "malignancy index" which quantifies the risk of the lesion becoming cancerous.

The test is based on a cancer gene encoding the Forkhead box protein (FOXM1) - (isoform B). The FOXM1 gene is highly expressed in many cancer types. The 14 associated genes are implicated in the regulation of the cell cycle, differentiation, aging, genomic stability, epigenetic and stem cell renewal. Two reference genes are included in the test.

Diagnostic test performance was assessed using detection rate (DR) and false-positive rate (FPR).The median qMIDS scores were 1.3, in healthy tissue, 2.9 in dysplasia, and 6.7 in head and neck squamous cell carcinomas (HNSCC).. At a qMIDS cut-off of 4.0, DR was 94% and FPR was 3.2% for a Norwegian dataset; and DR was 91% and FPR was 1.3% for the UK dataset. In this study, the investigators further demonstrated the transferability of qMIDS for diagnosing 58 premalignant human vulva and 21 skin squamous cell carcinomas, illustrating its potential clinical use for other cancer types.

Mouth cancer affects more than 6,200 people in the UK each year and more than half a million people worldwide, with global figures estimated to rise above one million a year by 2030. Muy-Teck Teh, PhD, the lead investigator and inventor of the test, said, “A sensitive test capable of quantifying a patient's cancer risk is needed to avoid the adoption of a 'wait-and-see' intervention. Detecting cancer early, coupled with appropriate treatment can significantly improve patient outcomes, reduce mortality and alleviate long-term public healthcare costs.” The study was published on October 4, 2012, in the journal International Journal of Cancer.

Related Links:

Queen Mary, University of London


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.